Related references
Note: Only part of the references are listed.A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07
N. Wolmark et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
R. Wong et al.
ANNALS OF ONCOLOGY (2011)
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer et al.
ANNALS OF ONCOLOGY (2011)
Antiepidermal growth factor receptor radiosensitizers in rectal cancer
Robert Glynne-Jones et al.
ANTI-CANCER DRUGS (2011)
Oxaliplatin: a review in the era of molecularly targeted therapy
T. Alcindor et al.
Current Oncology (2011)
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis
Francesco Montagnani et al.
GASTRIC CANCER (2011)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
Michel Ducreux et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.
A. De Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Greg Yothers et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
Carlo Aschele et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Matthew T. Seymour et al.
LANCET (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Richard A. Adams et al.
LANCET ONCOLOGY (2011)
Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975
C. La Vecchia et al.
ANNALS OF ONCOLOGY (2010)
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2010)
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up
R. Labianca et al.
ANNALS OF ONCOLOGY (2010)
Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
Luis E. Raez et al.
CLINICAL LUNG CANCER (2010)
Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection
Massimiliano Berretta et al.
CURRENT HIV RESEARCH (2010)
Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Entering My Final Year As Editor-in-Chief of Journal of Clinical Oncology
Daniel G. Haller
JOURNAL OF CLINICAL ONCOLOGY (2010)
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66
Steven R. Alberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
Jean-Pierre Gerard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Benoist Chibaudel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of transcription by platinum antitumor compounds
Ryan C. Todd et al.
METALLOMICS (2009)
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
D. Balin-Gauthier et al.
BRITISH JOURNAL OF CANCER (2008)
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Oxaliplatin-related neurotoxicity: Interest of calcium-magnesium infusion and no impact on its efficacy
Laurence Gamelin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
Brigit Gruenberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger et al.
LANCET (2008)
Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab
Marie Prewett et al.
CLINICAL CANCER RESEARCH (2007)
Actual 10-year survival after resection of colorectal liver Metastases defines cure
James S. Tomlinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:: Final report of the Spanish cooperative group for the treatment of digestive tumors trial
Eduardo Diaz-Rubio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group
Rainer Porschen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
Chris H. Takimoto et al.
CLINICAL CANCER RESEARCH (2007)
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: A National Cancer Institute Organ Dysfunction Working Group Study
Timothy W. Synold et al.
CLINICAL CANCER RESEARCH (2007)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
J. Philip Kuebler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
Richard M. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Oxaliplatin and axonal Na+ channel function in vivo
Arun V. Krishnan et al.
CLINICAL CANCER RESEARCH (2006)
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer:: The European Organisation for Research and Treatment of Cancer Chronotherapy group
Sylvie Giacchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
J Souglakos et al.
BRITISH JOURNAL OF CANCER (2006)
OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines
M Patel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin
SP Joel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis - A case report and review of the literature
AK Koutras et al.
ONCOLOGY (2004)
DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells
S Faivre et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
ML Rothenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cellular and molecular aspects of drugs of the future: oxaliplatin
AM Di Francesco et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Trends in long-term survival following liver resection for hepatic colorectal metastases
MA Choti et al.
ANNALS OF SURGERY (2002)
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat
G Cavaletti et al.
EUROPEAN JOURNAL OF CANCER (2001)
Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin
JG Morrison et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2000)
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
F Maindrault-Goebel et al.
ANNALS OF ONCOLOGY (2000)
Survival after resection of multiple hepatic colorectal metastases
SM Weber et al.
ANNALS OF SURGICAL ONCOLOGY (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
